TNFSF10 and hepatocellular carcinoma: Galal et al. confirmed that systemic therapy with an OAd inhibitor of growth 4 (ING4) and OAd-TRAIL elicited a more eradicative effect on the orthotopic mice model of human HCC than monotherapy, without apparent overlapping toxicity [94].